Table 2 HPV prevalence in breast cancer cases across region, HPV DNA source, and publication period
From: Inconclusive role of human papillomavirus infection in breast cancer
Variable | No. of studies | No. of cases | Proportion(%) | HPV prevalence (%) (95Â % CI) | P | OR (95%CI) | Adjusted ORa ( 95 % CI) |
|---|---|---|---|---|---|---|---|
Total | 38 | 2569 | 100 | 30.30(22.30–38.40) |  | … | … |
Region | Â | Â | Â | Â | <0.001 | Â | Â |
Oceania | 3 | 130 | 5.06 | 44.30(33.50–55.00) |  | Ref. | Ref. |
Asia | 16 | 1335 | 51.96 | 35.70(20.60–50.80) |  | 0.24(0.17–0.35) | 0.21(0.14–0.32) |
Europe | 9 | 467 | 18.18 | 32.60(6.50–58.70) |  | 0.17(0.11–0.27) | 0.09(0.05–0.14) |
South America | 7 | 522 | 20.32 | 14.60(5.80–23.50) |  | 0.14(0.09–0.21) | 0.07(0.04–0.11) |
North America | 3 | 115 | 4.48 | 10.70(4.40–17.00) |  | 0.14(0.07–0.28) | 0.06(0.03–0.13) |
HPV DNA source | Â | Â | Â | Â | 0.08 | Â | Â |
Fixed tissue | 24 | 1537 | 59.83 | 27.20(17.90–36.40) |  | Ref. | Ref. |
Fresh tissue | 14 | 1032 | 40.17 | 37.30(20.10–54.50) |  | 0.82(0.66–1.03) | 0.46(0.36–0.60) |
Publication period | Â | Â | Â | Â | 0 | Â | Â |
1992-2006 | 14 | 665 | 25.89 | 42.20(25.60–58.80) |  | Ref. | Ref. |
2007-2012 | 24 | 1904 | 74.11 | 22.60(14.40–30.70) |  | 0.37(0.30–0.46) | 0.26(0.20–0.33) |